A study with Lactobacillus reuteri Protectis DSM 17938 indicated that a species of the probiotic genus Lactobacillus may kill an antibiotic resistant bacterium. The findings are significant because they may enable prophylactic treatment with probiotics before taking antibiotics, which are know to disrupt good bacteria in the gut.
Read MoreBioGaia are proud sponsors of the iGEM Stockholm team. The team will participate in the world’s largest synthetic biology competition, The International Genetically Engineered Machine (iGEM) and consists of students from Karolinska Insitutet and Kungliga Tekniska Högskolan.
Read MoreComments from the Managing Director: “Sales in the second quarter of 2017 reached SEK 156 million, which is an increase of...
Read MoreBioGaia establishes a subsidiary, BioGaia Pharma AB, to take advantage of the opportunities to develop drugs identified in the research...
Read MoreThe Annual General Meeting of BioGaia AB (publ) on 3 May 2017 voted to approve the following resolutions: ·...
Read MoreA study with Lactobacillus reuteri Protectis DSM 17938 indicated that a species of the probiotic genus Lactobacillus may kill an antibiotic resistant bacterium. The findings are significant because they may enable prophylactic treatment with probiotics before taking antibiotics, which are know to disrupt good bacteria in the gut.
Read MoreBioGaia are proud sponsors of the iGEM Stockholm team. The team will participate in the world’s largest synthetic biology competition, The International Genetically Engineered Machine (iGEM) and consists of students from Karolinska Insitutet and Kungliga Tekniska Högskolan.
Read More